Medical Device Commercialization - Mynosys Cellular

Mynosys Cellular was formed to commercialize technologies developed by a UCSF professor of ophthalmology David Sretavan and Chris Keller PhD. to address a major challenge of cataract treatment – a repeatable, perfect capsulotomy. The other challenge John Hendrick, Mynosys CEO and the team faced was accelerating the commercialization process to give the new technology time to capture market share, becoming the standard of care for capsulotomies. Download the case study for the full story.